Publication Date



Objectives The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m2 and serum potassium < median of 123 mm Hg), examining the major safety measures (potassium > 5.5, > 6.0, and 5.5 mmol/l but not of potassium > 6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events. Eplerenone was effective in reducing the primary composite endpoint in all subgroups. Conclusions In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR > 30 ml/min/1.73 m2 and potassium


Mary MacKillop Institute for Health Research

Document Type

Open Access Journal Article

Access Rights

Open Access

Included in

Cardiology Commons